CW July 2004
Volume 13Issue Number 7 July 2004 ISSN 10593802 Aromatase Inhibitor Reduces Recurrences After TamoxifenA final analysis of a major trial of the 3rd generation aromatase inhibitor letrozole (Femara) shows significant reductions in breast cancer recurrence for both node positive and node negative disease and significantly increased overall survival for node positive disease.
Go to Previous Page Go to Next Page Source & Additional Reading Paul E. Goss, MD, Princess Margaret Hospital, Toronto, Canada, 40th Annual Meeting of the American Society of Clinical Oncology presentation. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW July 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
